120 related articles for article (PubMed ID: 23834146)
1. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.
Rossi M; Amodio N; Di Martino MT; Caracciolo D; Tagliaferri P; Tassone P
Curr Drug Targets; 2013 Sep; 14(10):1144-9. PubMed ID: 23834146
[TBL] [Abstract][Full Text] [Related]
2. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
Soliman AM; Lin TS; Mahakkanukrauh P; Das S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
[TBL] [Abstract][Full Text] [Related]
3. Trials and Tribulations of MicroRNA Therapeutics.
Seyhan AA
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338746
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.
Bhaskaran M; Mohan M
Vet Pathol; 2014 Jul; 51(4):759-74. PubMed ID: 24045890
[TBL] [Abstract][Full Text] [Related]
5. Development of microRNA-based therapeutics for central nervous system diseases.
Xia S; Xu C; Liu F; Chen G
Eur J Pharmacol; 2023 Oct; 956():175956. PubMed ID: 37541374
[TBL] [Abstract][Full Text] [Related]
6. MHESMMR: a multilevel model for predicting the regulation of miRNAs expression by small molecules.
Guan YJ; Yu CQ; Li LP; You ZH; Wei MM; Wang XF; Yang C; Guo LX
BMC Bioinformatics; 2024 Jan; 25(1):6. PubMed ID: 38166644
[TBL] [Abstract][Full Text] [Related]
7. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent nanodiamonds as innovative delivery systems for MiR-34a replacement in breast cancer.
Abate M; Lombardi A; Luce A; Porru M; Leonetti C; Bocchetti M; Campani V; De Rosa G; Graziano SF; Nele V; Cardile F; Marino FZ; Franco R; Ronchi A; Scrima M; Sperlongano R; Alfano R; Misso G; Amler E; Caraglia M; Zappavigna S
Mol Ther Nucleic Acids; 2023 Sep; 33():127-141. PubMed ID: 37449042
[TBL] [Abstract][Full Text] [Related]
9. TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.
Scionti F; Juli G; Rocca R; Polerà N; Nadai M; Grillone K; Caracciolo D; Riillo C; Altomare E; Ascrizzi S; Caparello B; Cerra M; Arbitrio M; Richter SN; Artese A; Alcaro S; Tagliaferri P; Tassone P; Di Martino MT
J Exp Clin Cancer Res; 2023 Mar; 42(1):71. PubMed ID: 36967378
[TBL] [Abstract][Full Text] [Related]
10. Non-Coding RNA-Dependent Regulation of Mitochondrial Dynamics in Cancer Pathophysiology.
Gallo Cantafio ME; Torcasio R; Viglietto G; Amodio N
Noncoding RNA; 2023 Feb; 9(1):. PubMed ID: 36827549
[TBL] [Abstract][Full Text] [Related]
11. Circulating MicroRNAs as Novel Potential Diagnostic Biomarkers for Osteosarcoma: A Systematic Review.
Gally TB; Aleluia MM; Borges GF; Kaneto CM
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680065
[TBL] [Abstract][Full Text] [Related]
12. miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma.
Caracciolo D; Riillo C; Juli G; Scionti F; Todoerti K; Polerà N; Grillone K; Fiorillo L; Arbitrio M; Di Martino MT; Neri A; Tagliaferri P; Tassone P
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503175
[No Abstract] [Full Text] [Related]
13. Roles of miRNA dysregulation in the pathogenesis of multiple myeloma.
Chen D; Yang X; Liu M; Zhang Z; Xing E
Cancer Gene Ther; 2021 Dec; 28(12):1256-1268. PubMed ID: 33402729
[TBL] [Abstract][Full Text] [Related]
14. Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.
Di Martino MT; Arbitrio M; Caracciolo D; Scionti F; Tagliaferri P; Tassone P
Mol Ther Nucleic Acids; 2020 Jun; 20():73-85. PubMed ID: 32146420
[TBL] [Abstract][Full Text] [Related]
15. Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.
Amodio N; Gallo Cantafio ME; Botta C; Agosti V; Federico C; Caracciolo D; Ronchetti D; Rossi M; Driessen C; Neri A; Tagliaferri P; Tassone P
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30781685
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.
Stamato MA; Juli G; Romeo E; Ronchetti D; Arbitrio M; Caracciolo D; Neri A; Tagliaferri P; Tassone P; Amodio N
Oncotarget; 2017 Dec; 8(63):106527-106537. PubMed ID: 29290968
[TBL] [Abstract][Full Text] [Related]
17. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
Zarone MR; Misso G; Grimaldi A; Zappavigna S; Russo M; Amler E; Di Martino MT; Amodio N; Tagliaferri P; Tassone P; Caraglia M
Sci Rep; 2017 Dec; 7(1):17949. PubMed ID: 29263373
[TBL] [Abstract][Full Text] [Related]
18. Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment.
Raimondi L; De Luca A; Costa V; Amodio N; Carina V; Bellavia D; Tassone P; Pagani S; Fini M; Alessandro R; Giavaresi G
Oncotarget; 2017 Nov; 8(59):100831-100851. PubMed ID: 29246026
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
